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Abstract	  
Controlled	  and	   localized	  delivery	  of	   Interleukin	  12	   (IL-­‐12)	   is	   critical	   to	  effective	  and	  non-­‐toxic	  
cancer	   immunotherapy.	   Current	   delivery	   protocols	   for	   pre-­‐clinical	   anti-­‐tumor	   trials	   utilize	  
solutions	  of	  chitosan,	  a	  mucoadhesive	  and	  bioeliminable	  biopolymer,	  to	  slow	  the	  release	  of	  IL-­‐
12	   into	   the	   tumor	   microenvironment.	   In	   order	   to	   further	   increase	   IL-­‐12	   retention,	   we	   have	  
developed	   and	   characterized	   two	   chitosan-­‐based	   in	   situ	   gelling	   hydrogels	   for	   IL-­‐12	  
immunotherapy.	   One	   hydrogel,	   composed	   of	   heparin	   and	   chitosan,	   is	   herein	   described	   from	  
initial	   conception	   through	  multiple	  stages	  of	  characterization	   including	   isolation	  of	  a	   range	  of	  
suitable	   hydrogel	   formulations	   and	  observational	   physical	   and	   chemical	   properties.	   A	   second	  
hydrogel	  is	  primarily	  composed	  of	  modified	  chitosan	  polymer.	  This	  hydrogel	  was	  characterized	  
in	  previous	  studies,	  but	  the	  release	  kinetics	  (in	  vitro	  and	   in	  vivo)	  were	  not	  defined.	  In	  order	  to	  
better	  understand	  this	  hydrogel,	  we	  performed	  both	  in	  vitro	  and	  in	  vivo	  protein	  release	  studies	  
that	  validate	  this	  platform	  as	  a	  candidate	  for	  improved	  IL-­‐12	  therapy.	  Results	  indicate	  that	  the	  
hydrogel	   and	  modified	   chitosan	   solution	   elicit	   protein	   retention	   at	   least	   twice	   as	  well	   as	   the	  
chitosan	   solution	   currently	   used.	   Future	   studies	   will	   further	   examine	   release	   kinetics	   of	   the	  
heparin-­‐chitosan	  hydrogel	  and	  the	  anti-­‐tumor	  response	  in	  mouse	  models	  using	  both	  hydrogels.	  
If	  successful,	  these	  IL-­‐12/hydrogel	  formulations	  will	  provide	  new	  clinical	  treatments	  for	  patients	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1.	  Introduction	  
There	   were	   approximately	   14	   million	   new	   cancer	   diagnoses	   and	   8.2	   million	   cancer-­‐
related	   deaths	   worldwide	   in	   2015.1	   Cancer	   and	   its	   associated	   ailments	   are	   the	   second-­‐most	  
deadly	  diseases	   in	  the	  US,	  only	  barely	  outnumbered	  by	  heart	  disease.	   In	  2011,	  direct	  medical	  
costs	  (exclusive	  of	  moneys	  spent	  on	  cancer	  research)	  associated	  with	  cancer	  treatment	  reached	  
nearly	   90	   billion	   dollars	   in	   the	   US,	   signifying	   a	   significant—and	   in	   some	   cases	   futile—	  
consumption	   of	   our	   current	   technologies	   and	   a	   need	   for	   further	   development.1	   For	   these	  
reasons,	  the	  demand	  for	  improving	  and	  innovating	  diagnostic	  techniques	  and	  treatments	  is	  well	  
warranted;	  interest	  in	  improving	  cancer	  diagnosis	  and	  treatment	  capabilities	  benefits	  both	  the	  
global	  healthcare	  system	  and	  economy.	  	  
Unfortunately,	   many	   cancers	   go	   unchecked	   until	   they	   are	   large	   enough	   to	   cause	  
physiological	   side	   effects	   that	   prompt	   the	   patient	   to	   seek	   a	   doctor.	   	   Because	  many	   primary	  
tumors	  often	  have	  to	  grow	  quite	  extensively	  before	  being	  noticed,	  prognosis	  is	  often—but	  not	  
always—poor	   by	   the	   time	   help	   is	   sought.2	   Treatment	   options	   for	   cancer	   patients	   include	  
surgical	  excision,	   chemotherapy,	   radiotherapy,	  hormone	   therapy	  and	   immunotherapy.3	  These	  
modalities	   are	   typically	   used	   in	   concert;	   for	   example,	   the	  majority	   of	   a	   breast	   cancer	   lumps	  
could	   be	   surgically	   removed,	   but	   then	   the	   subject	  would	   undergo	   rounds	   of	   radiotherapy	   to	  
eradicate	  the	  remainder	  of	  the	  cancerous	  cells	  in	  the	  tissue.1	  	  While	  this	  seems	  simple	  in	  theory,	  
the	  clinical	  outcomes	  are	   far	   from	   ideal,	   resulting	   in	  millions	  of	  deaths	  worldwide	  every	  year.	  	  
Furthermore,	   even	   if	   primary	   treatment	   is	   successful,	   current	   treatments	   cannot	   target	   and	  
eliminate	  metastases	  and	  prevent	  recurrence.	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Cancer	   immunotherapy	   is	   a	   rapidly	   advancing	   approach	   that	   is	   defined	   as	   the	  
mobilization	   of	   the	   host’s	   immune	   system	   to	   eliminate	   relieve,	   or	   suppress	   disease.4	   The	  
potential	   of	   immunotherapy	   as	   a	   standalone	   or	   joint	   treatment	   option	   has	   become	   more	  
attractive	   in	   recent	   years;	   the	   last	   decade	   has	   yielded	   163,000	   publications	   on	   cancer	  
immunotherapy,	  up	  from	  52,600	  in	  the	  previous	  decade.5	  	  
At	   the	  most	   basic	   level,	   immunotherapies	   function	   by	  modification	   of	   immunological	  
pathways.	   Cancer	   immunotherapy	   can	   be	   divided	   into	   four	   modalities—checkpoint	  
modification,	   mature	   immune	   cell	   therapy,	   cell-­‐specific	   vaccination,	   and	   immune	   system	  
modulation—that	   can	   be	   implemented	   alone	   or	   in	   concert	   with	   each	   other—and	   with	   non-­‐
immunotherapeutic	  approaches—	  to	  varying	  effect.4	  	  
Immune	   system	  modulation	   requires	   the	   delivery	   of	   cytokines,	   co-­‐factors,	   and	   other	  
signaling	   molecules	   to	   mobilize	   the	   immune	   system.	   These	   modulators	   include	   a	   class	   of	  
molecules	  called	  ‘interleukins’.	  Interleukins	  such	  as	  interleukin	  2	  (IL-­‐2)	  and	  interleukin	  12	  (IL-­‐12)	  
are	   integral	   to	   the	   immunological	   pathways	   of	   adaptive	   immunity,	   and	   can	   help	   the	   body	  
recognize,	  fight,	  and	  eliminate	  solid	  primary	  tumors	  and	  their	  subsequent	  metastases.6	  In	  many	  
cases,	   after	   tumor	   elimination,	   a	   ‘memory’	   is	   established	   to	   prevent	   disease	   remission.	  
Immunotherapy	  is	  not	  without	  its	  challenges.	  Outside	  of	  the	  treatment’s	  effective	  therapeutic	  
window,	  the	  therapy	  can	  be	  either	  ineffective	  or	  hypereffective.	  Hypereffective	  treatment	  leads	  
to	  systemic	  autoimmune	  toxicity,	  organ	  failure,	  and	  death.	  For	  this	  reason,	  controlled	  delivery	  
of	  therapeutics	  is	  crucial	  to	  effective	  treatment.	  	  
Drug	   delivery	   mechanisms	   range	   from	   drug-­‐releasing	   nanoparticles	   to	   hydrogels	   that	  
release	   the	   drug	   into	   the	   microenvironment	   as	   the	   structure	   breaks	   down.	   A	   variety	   of	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materials	  and	  tools	  provide	  the	  ability	  to	  create	  site-­‐	  and	  drug-­‐specific	  platforms	  for	  delivering	  
an	  effective	  quantity	  drug	  to	  a	  very	  specific	  target	  over	  an	  appropriate	  amount	  of	  time.7	  	  	  
The	  discovery,	  characterization,	  and	  implementation	  of	  novel	  delivery	  mechanisms	  are	  	  
core	   research	   themes	   in	   the	   University	   of	   Arkansas’s	   Laboratory	   for	   Vaccine	   and	  
Immunotherapy	  Delivery	  (LVID).	  Much	  of	  the	  LVID’s	  past	  publications	  are	  focused	  on	  immune	  
system	  modulation	  using	  co-­‐formulations	  of	   interleukin	  12	  (IL-­‐12)	  and	  chitosan	  (CS),	  a	  viscous	  
biopolymer	  derived	  primarily	  from	  crustacean	  shells	  and	  fungi.8,9	  Chitosan’s	  functional	  groups,	  
physicochemical	  properties,	  and	  average	  molecular	  weight	  (length)	  are	  highly	  variable,	  making	  
it	  attractive	  for	  drug	  delivery	  applications,	  as	  it	  can	  be	  fine	  tuned	  for	  specific	  needs	  such	  as	  oral	  
drug	  delivery	  and	  wound	  healing.10	  IL-­‐12	  is	  a	  cytokine,	  a	  cell-­‐signaling	  molecule,	  that	  is	  released	  
in	  the	  presence	  of	  infection	  and	  promotes	  differentiation	  of	  T	  cells	  (a	  type	  of	  immune	  cell)	  into	  
Th1	   cells.	   Th1	   cells	   secrete	   interferon	   gamma	   (IFN-­‐γ),	   IL-­‐2,	   and	   lymphotoxin,	   which	   result	   in	  
further	  cell-­‐mediated	  offense.11	  After	  the	  infection	  has	  been	  eliminated,	  some	  of	  the	  activated	  
B	   cells	  will	   differentiate	   into	  memory	   cells	   that	   re-­‐stimulate	   the	   immune	   system	   if	   the	   same	  
tumor	  cells	  types	  begin	  to	  grow	  again.12	  
Previous	   publications	   from	   the	   LVID	   demonstrate	   intratumoral	   injection	   of	   IL-­‐
12/chitosan	   mixtures	   and	   the	   subsequent	   anti-­‐tumor	   effects	   (for	   some	   cell	   types)	   and	   cell-­‐
specific	  immunity	  that	  follows	  disease	  eradication.8,9	  	  However,	  these	  mixtures	  have	  been	  less	  
effective	   against	   triple-­‐negative	   breast	   cancer	   cells	   (TNBC)	   and	   other	   aggressive	   cancer	   cell	  
lines.9	  It	  is	  believed	  that	  by	  further	  increasing	  and	  retaining	  concentrated	  intratumoral	  IL-­‐12	  will	  
provide	  sufficient	  immune	  stimulation	  for	  tumor	  eradication	  of	  these	  more	  resilient	  tumors.	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To	  attempt	  to	  increase	  retention,	  we	  aim	  to	  develop,	  characterize,	  and	  implement	  novel	  
hydrogels	   that	   can	   be	   loaded	   with	   IL-­‐12	   and	   injected	   directly	   into	   the	   tumor.	   	   Christopher	  
Wallace	  and	  Dr.	  Bhanu	  Koppolu	  of	  the	  LVID	  developed	  one	  hydrogel	  of	  interest.13	  The	  hydrogel	  
is	  composed	  of	  modified	  chitosan	  (mCS)	  and	  crosslinking	  agents	  that	  form	  rapidly	  upon	  mixing.	  
This	   hydrogel	   is	   proposed	   to	   follow	   a	   cross-­‐linked	   polymer	   chain	  model,	   as	   described	   in	   the	  
figure	   below	   (Figure	   1).	   In	   this	  model,	   crosslinking	  molecules	   conjoin	   the	   side	   groups	   of	   the	  
primary	  polymer	  to	  form	  a	  mesh	  network.14	  	  
	  
Figure	  1:	  Cross-­‐linked	  Hydrogels	  
The	  gelation	  parameters,	  hydrogel	  modulation	  of	  IL-­‐12	  bioactivity,	  and	  anti-­‐tumor	  activity	  were	  
previously	   assessed.13	   Investigations	   of	   this	   hydrogel	   included	   in	   this	   article	   include	   the	  
development	  and	  implementation	  of	  a	  protocol	  to	  determine	  relative	  release	  kinetics,	  both	   in	  
vitro	  and	  in	  vivo,	  and	  develop	  a	  pathway	  for	  further	  investigation.	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A	   second	   chitosan-­‐based	   hydrogel	   that	   co-­‐formulates	   chitosan	   with	   heparin	   (Hep),	   a	  
biopolymer	  typically	  used	   in	  medicine	  as	  an	  anticoagulant.15	  Heparin	  contains	  protein-­‐binding	  
sites	  very	  specific	  to	  IL-­‐12	  and	  other	  cytokines;	  using	  this	  polymer	  in	  the	  hydrogel	  matrix	  may	  
further	   inhibit	   IL-­‐12	   dissemination	   and	   thus	   increase	   immune	   response	   and	   treatment	  
capability.16	  This	  heparin-­‐chitosan	   (Hep-­‐CS)	  hydrogel	   forms	   instantaneously,	  as	   the	  oppositely	  
charged	  polymer	  chains	  electrostatically	  attract	  and	  irreversibly	  bind.	  	  This	  hydrogel	  is	  classified	  
as	  an	  ionic	  hydrogel,	  as	  the	  electrostatic	  forces	  between	  the	  polymers	  are	  the	  driving	  force	  of	  
gelation.14	  The	  figure	  below	  (Figure	  2)	  demonstrates	  this	  phenomenon.	  
	   	  
Figure	  2:	  Ionic	  Hydrogels	  
Investigations	   include	   the	   determination	   of	   how	   component	   concentrations	   contribute	   to	  
hydrogel	   formation,	   the	   quantification	   of	   hydrogel	   formation	   using	   different	   methods,	   and	  
determination	  of	  a	  key	  physico-­‐chemical	  property	  of	  the	  hydrogel,	   the	   lower	  critical	  solubility	  
temperature	  (LCST).	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The	  methods,	  data,	  and	  analysis	  herein	  describe	  the	  processes,	  results,	  and	  conclusions	  
regarding	   the	   investigation	  of	   these	   two	  novel	  hydrogels	   and	   their	  potential	   for	   intratumoral	  
delivery	  of	   IL-­‐12.	   If	   successful,	   these	  studies	  will	   substantiate	   the	  belief	   that	   robust	  hydrogels	  
are	  solid	  potential	  candidates	  for	  pre-­‐clinical	  anti-­‐tumor	  trials.	  	  
2.	  Materials	  and	  Methods	  
2.1	  Heparin-­‐Chitosan	  Hydrogel	  
	   2.1.1	  Hydrogel	  Preparation	  
Initial	   hydrogel	   preparation	   was	   entirely	   experimental.	   Solutions	   of	   heparin	   (H3393,	  
Sigma-­‐Aldrich)	   were	   prepared	   in	   DPBS	   at	   105,	   50,	   25,	   15,	   10,	   7.5,	   5,	   2m,	   1,	   and	  
0.1mg/mL.	   Chitosan	   (Chitoclear,	   Primex)	   solutions	   of	   different	   viscosities	   (2-­‐20cP,	   20-­‐
200cP,	   200-­‐600cP,	   and	  600-­‐2000cP)	  were	  prepared	   in	   2%	  acetic	   acid	   at	   5,	   2.5,	   1,	   and	  
0.1mg/mL.	  Equal	  volumes	  of	  heparin	  and	  chitosan	  were	  combined.	  Concentrations	  and	  
chitosan	   viscosities	   were	   varied	   and	   the	   resulting	   hydrogels	   were	   observed.	   General	  
bounds	   for	   gelation	   were	   established	   by	   visual	   confirmation	   of	   gelation;	   select	  
combinations	  were	  used	  for	  future	  studies.	  See	  Protocol	  1	  for	  details.	  
	   2.1.2	  Colorimetric	  Assay	  for	  Hydrogel	  Optimization	  
Total	   hydrogel	   formation	   can	   be	   optimized	   by	   selecting	   chitosan	   and	   heparin	  
concentrations	  that,	  when	  reacted,	  do	  not	   leave	  excess	  polymer	  in	  solution.	  Hydrogels	  
were	  prepared	  per	  Protocol	  1	  in	  triplicate	  using	  low	  viscosity	  (2-­‐20	  cP)	  chitosan	  at	  5,	  2.5,	  
and	  1	  mg/mL	  and	  heparin	  at	  15,	  10	  5,	  and	  1	  mg/mL.	  Samples	  were	  homogenized	  using	  a	  
benchtop	  vortex	  and	  then	  centrifuged	  to	  pellet	  the	  hydrogel	  particles.	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The	   remaining	   supernatant	  was	   removed	  and	  used	   in	   the	   assay.	   	  Dilutions	  of	   heparin	  
and	   chitosan	   were	   prepared	   as	   controls.	   This	   spectrometric	   detection	   assay	   was	  
adapted	   from	  Badawy	  et	   al.	   using	  2-­‐thiobarbituric	   acid	   (Sigma-­‐Aldrich),	   sodium	  nitrite	  
(Sigma-­‐Aldrich),	  and	  sodium	  hydroxide	  (Sigma-­‐Aldrich);	  see	  Protocol	  2	  for	  details.17	  
	   2.1.3	  Absorptivity	  Assay	  for	  Hydrogel	  Optimization	  
The	   hydrogel	   formation	   reaction	   results	   in	   Hep-­‐CS	   hydrogels	   non-­‐homogenous	   white	  
coloration	  to	  varying	  degrees,	  dependent	  on	  the	  concentrations	  of	   the	  constituents.	   If	  
formation	  of	  white	   coloration	   is	   a	  measure	  of	  heparin-­‐chitosan	   interaction,	   increasing	  
coloration	  indicates	  a	  more	  reacted	  hydrogel.	  	  
Hydrogels	  were	  prepared	  in	  triplicate	  using	  2-­‐20	  cP	  chitosan	  at	  5,	  2.5,	  and	  1	  mg/mL	  and	  
105,	  50,	  25,	  15,	  10,	  5,	  and	  1,	  0.5,	  and	  0.1	  mg/mL	  heparin.	  Hydrogels	  were	  vortexed	  for	  5	  
seconds	  upon	  combination	  of	  reactants,	  then	  again	  for	  10	  seconds	  prior	  to	  distribution	  
to	   a	   96-­‐well	   plate.	   Dilutions	   of	   chitosan	   and	   heparin	   were	   prepared	   and	   used	   to	  
differentiate	   between	   reacted	   and	   unreacted	   hydrogels.	   PBS	   was	   used	   to	   determine	  
background	  absorbance	  of	  the	  plate.	  Absorbance	  spectra	  of	  samples	  were	  read	  using	  a	  
spectrophotometer.	  
	   2.1.4	  Thermosensitivity	  Assessment,	  LCST	  
Hydrogels	  were	  prepared	  in	  triplicate	  using	  10mg/mL	  heparin	  and	  5mg/mL	  chitosan	  of	  
viscosity	   20-­‐200	   cP.	   Immediately	   after	   combination	   of	   heparin	   and	   chitosan,	   samples	  
were	   incubated	   for	   1	   hour	   in	   environments	   of	   70,	   55,	   37,	   27,	   and	   4C.	   Samples	  were	  
removed,	  photographed,	  and	  observed	  upon	  completion.	  
2.2	  mChitosan	  Hydrogel	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   2.2.1	  Hydrogel	  Preparation	  
Hydrogels	   were	   prepared	   using	   a	   proprietary	   formulation	   composed	   of	   the	   primary	  
modified	   chitosan	   polymer	   (mCS),	   crosslinking	   agent	   (X),	   and	   a	   catalyst.	   This	   protocol	  
was	  established	  in	  a	  previous	  study	  at	  the	  LVID	  and	  is	  not	  listed	  herein.	  
	   2.2.2	  In	  Vitro	  Release	  Kinetics	  
Using	   fluoroisothiocyanate-­‐tagged	   bovine	   serum	   albumin	   protein	   (FITC-­‐BSA)	  
Triplicates	   of	   release	   solutions	   (PBS,	   0.5%	  m/v	  mCS,	   and	  mCS	   hydrogel)	   were	   loaded	  
with	  50	  ug	  FITC-­‐BSA	  (Sigma-­‐Aldrich)	  and	  injected	  into	  1	  mL	  Float-­‐A-­‐Lyzer	  (100kd	  MWCO)	  
floating	  dialysis	  	  tubes	  (Spectrum	  Labs).	  Loaded	  tubes	  were	  placed	  in	  15	  mL	  PBS	  in	  a	  50	  
mL	   centrifuge	   tube	   and	   incubated	   in	   a	   37C	   shaker	   at	   200	   rpm.	   1	  mL	   samples	   of	   PBS	  
dialysate	  were	  removed	  and	  1	  mL	  fresh	  PBS	  was	  added	  at	  3,	  6,	  12,	  24,	  48,	  72,	  96,	  120,	  
144,	  and	  168	  hours.	  Samples	  were	  kept	  at	  room	  temperature	  until	  study	  was	  concluded,	  
then	  fluorescence	  of	  all	  samples	  were	  read	  using	  a	  BioTek	  Synergy	  2	  spectrofluorometer	  
with	  a	  FITC	  excitation	  and	  emission	  filter	  set.	  
Post-­‐study	   investigations	   confirm	   fluorescent	   instability	   and	   recoverability	   of	   the	   FITC	  
tag.	  
Using	  Alexa	  Fluor	  488	  (AF488)	  	  
Prior	   to	   release	   study,	   pH	   stability	   and	   transient	   stability	   of	  AF488	   (Life	   Technologies)	  
were	  examined.	  
50	  micrograms	   of	   hIL-­‐12/AF488	  was	   released	   300kD	  MWCO	   Float-­‐A-­‐Lyzers	   into	   25mL	  
PBS	  dialysate.	   Release	   solutions	  were	  PBS,	  mCS	   (0.5%	  w/v),	   and	  mCS	  hydrogel.	   Tubes	  
were	   incubated	  at	  37C	  at	  200	  rpm.	  200uL	  samples	  of	  dialysate	  were	  taken	  at	  3,	  6,	  12,	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24,	  48,	  72,	  96,	  120,	  144,	  and	  168	  hours.	  Samples	  were	  kept	  at	  room	  temperature	  until	  
the	  study	  was	  concluded.	  100	  uL	  of	  the	  200	  uL	  sample	  were	  read	  using	  a	  BioTek	  Synergy	  
2	  spectrofluorometer	  with	  a	  FITC	  excitation	  and	  emission	   filter	  set.	  See	  Protocol	   3	   for	  
details.	  
	   2.2.3	  In	  Vivo	  IL-­‐12	  Retention	  in	  mCS	  hydrogel,	  mCS	  solution,	  and	  PBS	  
mIL-­‐12	   (Arkansas	  Biologics	  Center)	  was	   first	   tagged	  with	  AlexuaFluor	  660	   (AF660)	   (Life	  
Technologies,	   USA)	   following	   standard	   product	   protocol.	   Mice	   (n=3	   per	   group)	   were	  
subcutaneously	   injected	  with	  100	  uL	  of	  mCS,	  PBS,	  and	  mCS	  hydrogel	   loaded	  with	  1	  ug	  
mIL-­‐12/AF660.	   Mice	   were	   imaged	   using	   an	   IVIS	   Lumina	   Pre-­‐Clinical	   Imaging	   System	  
minutes	  after	   injection	  and	  1,	  2,	  3,	  4,	  6,	  7,	  10,	  and	  14	  days	   later,	  or	  until	   fluorescence	  
was	  no	  longer	  significant.	  Regions	  of	  interest	  (ROIs)	  were	  drawn	  around	  injection	  site	  in	  
the	   digital	   images,	   and	   radiant	   efficiency	   for	   each	   mouse	   at	   each	   time	   point	   was	  
calculated	  using	  the	  image	  capture	  software	  and	  tools.	  Data	  was	  processed	  and	  graphed	  
using	  Microsoft	  Excel.	  
2.2.4	  	  In	  Vivo	  Comparison	  of	  mCS	  and	  Protasan	  
mCS	  and	  Protasan	  solutions	  were	  prepared	  and	   loaded	  with	  1	  ug	  mIL-­‐12/AF660.	  Mice	  
(n=3	  per	  group)	  were	  subcutaneously	  injected	  with	  100	  uL	  of	  either	  mCS-­‐IL12/AF660	  or	  
Protasan-­‐IL12/AF660.	   Mice	   were	   imaged	   using	   an	   IVIS	   Lumina	   Pre-­‐Clinical	   Imaging	  
System	  minutes	  after	  injection	  and	  1,	  2,	  3,	  4,	  5,	  6,	  and	  7	  days	  later.	  Regions	  of	  interest	  
(ROIs)	  were	  drawn	  around	  injection	  site	  in	  the	  digital	  images,	  and	  radiant	  efficiency	  for	  
each	  mouse	   at	   each	   time	  point	  was	   calculated	  using	   the	   image	   capture	   software	   and	  
tools.	  Data	  was	  processed	  and	  graphed	  using	  Microsoft	  Excel.	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3.	  Results	  
3.1	  Heparin-­‐Chitosan	  Hydrogel	  
3.1.1	  Hydrogel	  Preparation	  
Figure	  3	  (below)	  shows	  four	  prepared	  samples	  using	  1:5,	  2:1,	  10:1,	  and	  21:1	  heparin-­‐to-­‐
chitosan	  ratios.	  Degree	  of	  gelation	  was	  determined	  visually	  by	   inversion,	  by	  density	  of	  
white	  coloration,	  and	  gel	  volume	  fraction.	  Order	  of	  decreasing	  degree	  of	  gelation	  is	  as	  
follows:	  2:1à10:1à21:1à1:5	  
	  
Figure	  3:	  Heparin-­‐Chitosan	  Hydrogel	  Examples.	   	  Heparin:Chitosan	  ratios	   from	  left	   to	  right	  are	  1:5,	  2:1,	  
10:1,	  and	  21:1.	  The	  2:1	  hydrogel	  was	  observed	  to	  be	  the	  most	  robust	  and	  fully-­‐reacted.	  
3.1.2	  Colorimetric	  Assay	  for	  Hydrogel	  Optimization	  
Figure	   4	   shows	   a	   96-­‐well	   plate	   containing	   3	   concentrations	   of	   heparin	   and	   3	  
concentrations	   of	   chitosan.	   Each	   sample	   concentration	   has	   been	   diluted	   into	   four	  
buffers	   with	   different	   pH.	   It	   was	   determined	   that	   chitosan	   and	   heparin	   cause	   similar	  
changes	   in	   color	   across	   a	   range	   of	   pH	   values	   (4-­‐7).	   Similar	   coloration	   is	   observed	   at	  
between	   the	   two	   reacted	   polymers.	   As	   pH	   increases	   (from	   left	   to	   right,	   starting	   at	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columns	   1,	   5,	   and	   9),	   becomes	   less	   reactive	   and	   heparin	   becomes	   more	   reactive.	  
Chitosan	  and	  heparin	  yield	  the	  same	  absorbance	  peak	  to	  varying	  degree,	  depending	  on	  
concentration	  and	  pH,	  making	  mixtures	  of	  the	  two	  solutions	  impossible	  to	  discern.	  
	  
Figure	  4:	  Calorimetric	  Assay	  
3.1.3	  Absorptivity	  Assay	  for	  Hydrogel	  Optimization	  
Hydrogel	   absorption	   at	   300nm	  was	   used	   to	   quantify	   degree	   of	   gelation.	   According	   to	  
absorptivity	   curves	   in	  Figure	   5,	  optimization	  occurs	  at	  1-­‐2:1	  m/m	  heparin	   to	  chitosan;	  














Heparin	  Concentration	  (mg/mL)	  
5mg/mL	  Chitosan	  2.5	  mg/mL	  Chitosan	  1	  mg/mL	  Chitosan	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Figure	  5:	  Absorption	  of	  Varying	  Hydrogels	  at	  300nm	  
3.1.4	  Thermosensitivity	  Assessment	  
	  
Figure	  6:	  Hydrogel	   Samples	   at	   Extreme	  Temperatures.	   Immersion	   temperatures	  decrease	   from	   left	   to	  
right.	  Sample	  1	  was	  immersed	  in	  70C,	  sample	  2	  was	  immersed	  in	  55C,	  sample	  3	  was	  in	  37C,	  sample	  4	  was	  
in	  27C,	  and	  sample	  5	  was	  in	  4C.	  
Hydrogel	   collapse—characterized	   by	   dense	   white	   hydrogel—	   is	   observed	   above	   the	  
structure’s	  lower	  critical	  solution	  temperature.	  Partial	  collapse	  is	  observed	  at	  55C,	  with	  
total	   collapse	   at	   70C.	   LCST,	   then,	   is	   approximately	   55C.	   An	   exact	   LCST	   is	   under	  
evaluation.	  
3.2	  mChitosan	  Hydrogel	  
3.2.1	  Hydrogel	  Preparation	  	  
Figure	   7	   displays	   samples	   of	   hydrogel	   components	   (three	   leftmost	   tubes)	   and	  hydrogel	   (right)	   loaded	   with	   FITC-­‐BSA,	   a	   fluorescent	   marker,	   and	   inverted.	   The	  hydrogel	   retains	   shape	   and	   remains	   at	   the	   ‘bottom’	   of	   the	   tube,	   whereas	   liquid	  components	  do	  not.	  
1	   2	   3	   4	   5	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Figure	  7:	  mCS	  Hydrogel	  Preparation	  
	   3.2.2	  In	  Vitro	  Release	  Kinetics	  
The	  initial	  release	  study	  using	  FITC-­‐BSA	  was	  deemed	  unsuccessful	  from	  the	  total	  lack	  of	  
measured	  fluorescence	  exemplified	  in	  Figure	  8.	  	  
	  


















Incubation	  Time	  (hours)	  
Chitosan	  PBS	  
16	  
The	  Investigation	  of	  Chitosan-­‐based	  Hydrogels	  for	  Controlled	  Intratumoral	  Release	  of	  Anti-­‐tumor	  Cytokines	  	  
	   	  
Figure	  9:	  pH	  Dependence	  of	  FITC-­‐BSA	  Fluorescence	  
Figure	   9	   indicates	  high	  variability	  of	  FITC	   fluorescence	  when	   incubated	   in	  different	  pH	  
buffers.	  Figure	  10,	  however,	  shows	  almost	  complete	  recovery	  in	  fluorescence	  when	  pH	  
is	  adjusted	  from	  low	  to	  high.	  Fluorescence	  is	  almost	  completely	  depleted	  at	  a	  pH	  of	  3,	  
but	  recovers	  86%	  of	  fluorescence	  when	  adjusted	  up	  to	  8.	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Figure	  11	  indicates	  that,	  between	  a	  pH	  of	  5.6	  and	  7.9,	  fluorescence	  of	  IL-­‐12/AF488	  does	  
not	   vary	   significantly,	   which	   indicates	   that	   it	   can	   be	   implemented	   in	   release	   studies	  
using	  release	  solutions	  of	  varying	  pH.	  	  
	  
Figure	  11:	  pH	  Dependence	  of	  IL-­‐12/AF488	  Fluorescence	  
Figure	  12	  shows	  about	  ±10%	  fluctuation	  from	  the	  initial	  and	  final	  fluorescence	  
measurements	  over	  a	  period	  of	  one	  week.	  
	  
Figure	  12:	  Transient	  Stability	  of	  IL-­‐12/AF488	  
Release	   profiles	   of	   IL-­‐12/AF488	   from	   a	   study	   comparing	   PBS	   release	   from	   300kD	   and	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MWCO	  Float-­‐A-­‐Lyzers	  release	  nearly	  twice	  as	  much	  protein	  as	  100kD	  Float-­‐A-­‐Lyzers	  in	  a	  
period	  of	  48	  hours.	  
	  
Figure	  13:	  IL-­‐12/AF488	  Release	  from	  100kD	  and	  300kD	  MWCO	  Float-­‐A-­‐Lyzer	  Tubes	  	  Final	  release	  profiles	  of	  IL-­‐12/AF488	  from	  PBS,	  mCS	  solution	  and	  mCS	  hydrogel	  are	  shown	  below	  in	  Figure	  14.	  The	  PBS	  curve	  is	  relatively	  linear,	  with	  approximately	  45%	  of	  protein	  released	  after	  one	  week.	  Modified	  chitosan	  solution	  inhibits	  IL-­‐12/AF488	  release,	  reducing	  cumulative	  release	  from	  45%	  to	  16%.	  The	  hydrogel	  displays	  kinetics	  similar	  to	  PBS	  for	  the	  first	  24	  hours,	  then	  prevents	  release	  for	  the	  remainder	  of	  the	  7	  days,	  with	  a	  total	  of	  approximately	  8%.	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3.2.3	  In	  Vivo	  Hydrogel	  IL-­‐12	  Retention	  
Figure	   15	   displays	   retention	  of	   IL-­‐12/AF660	  calculated	  by	  comparing	   the	   radiant	  efficiency	   of	   each	   time	   point	   to	   the	   initial	   radiant	   efficiency	   (RE).	   The	   photos	   in	  
Figure	  16	  are	  scaled	  to	  the	  same	  RE	  upper	  and	  lower	  bounds	  for	  direct	  comparison	  between	   groups.	   Figure	   15	   and	   Figure	   16	   show	   the	   drastic	   dispersion	   of	   IL-­‐12/AF660	   from	   the	   PBS	   injections	   after	   24	   hours.	   	   The	   photos	   indicate	   a	   lower	  initial	   fluorescence	   in	   the	   hydrogel	   mice	   and	   that	   most	   of	   the	   protein	   is	  disseminated	  quickly.	   	  The	  graph,	  however,	  indicates	  that	  15-­‐20%	  of	  the	  protein	  is	  retained	   for	   seven	   days,	   and	   the	   remainder	   is	   lost	   by	   day	   14;	   this	   elevated	   and	  potentially	  mis-­‐representative	  value	  can	  be	  attributed	  to	  the	  relatively	  low	  amount	  of	  protein	  at	   the	   initial	   time	  point.	  Modified	  chitosan	  solution	  elicits	  much	  greater	  control	   on	   dissemination	   of	   protein.	   After	   10	   days,	   mCS	   solution	   injection	   has	  retained	  twice	  the	  amount	  of	   initial	   fluorescent	  protein	  than	  the	  mCS	  hydrogel.	  14	  days	  from	  initial	  injection,	  all	  fluorescent	  protein	  was	  gone	  from	  mCS	  hydrogel	  mice	  while	  mCS	  solution	  mice	  showed	  retention	  of	  12%.	  	  The	  PBS	  and	  mCS	  solution	  mice	  start	   with	   approximately	   the	   same	   amount	   of	   protein	   at	   the	   injection	   site.	  Fluorescence	  is	  still	  visible	  in	  the	  mCS	  solution	  mice	  at	  day	  20,	  where	  PBS	  mice	  have	  no	  remaining	  fluorescence	  after	  24	  hours	  and	  mCS	  solution	  mice	  have	  no	  remaining	  fluorescence	  at	  10	  days.	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Figure	  15	  :	  Percent	  Retention	  IL-­‐12/AF660	  Retention	  In	  Vivo	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3.2.4	  	  In	  Vivo	  Comparison	  of	  mCS	  and	  the	  LVID’s	  Standard	  Practice	  Delivery	  System	  	  
This	  investigation	  revealed	  a	  nearly	  5-­‐fold	  increase	  in	  localized	  IL-­‐12/AF660	  retention	  by	  
mCS	   solution	   over	   Protasan	   after	   1	  week.	   Percent	   retention	  was	   calculated	   point-­‐by-­‐
point,	  as	  a	  comparison	  of	  the	  magnitude	  of	  radiant	  efficiency	  to	  the	  initial	  value	  at	  time	  
of	   injection.	  After	  7	  days,	  mCS	  solution	  retained	  approximately	  10%	  IL-­‐12/AF660	  while	  
Protasan	   retained	   approximately	   2%.	   The	   data	   for	   mCS	   does	   not	   agree	   with	   the	  
retention	  results	  from	  the	  previous	  study	  so	  repeat	  studies	  will	  be	  conducted	  to	  confirm	  
results.	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4.	  Discussion	  
The	   two	   hydrogels	   have	   presented	   unique	   challenges	   to	   characterization	   and	  
implementation	   in	   pre-­‐clinical	   studies.	   Pre-­‐clinical	   studies	   rely	   heavily	   on	   a	   base	   of	  
characterization	  studies	  that	  lend	  credibility	  to	  the	  platform	  and	  suggest	  that	  experimentation	  
is	  not	  without	  reason.	  
The	  heparin-­‐chitosan	  hydrogel	  is	  in	  very	  early	  stages	  of	  investigation.	  The	  nature	  of	  early	  
experimentation	   is	   innately	   slow	   and	   arduous.	   Though	   creation,	   manipulation,	   and	   visual	  
observation	   of	   these	   hydrogels	   is	   simple,	   quantification	   of	   characteristics	   such	   as	   degree	   of	  
gelation	  or	   reaction,	  determination	  of	  excess	  polymer	   in	  solution,	  and	  LCST	   is	  more	  complex,	  
unclear,	   and	   non-­‐resolute.	   We	   have	   isolated	   a	   range	   of	   concentrations	   and	   viscosities	   of	  
heparin	  and	  chitosan	  that	  combine	  to	  make	  robust	  gels	  that	  do	  not	  degrade	  via	  hydrolysis	  or	  
other	  non-­‐biological	  pathways	  over	  the	  span	  of	  3	  weeks,	  even	  at	  37C.	  	  
The	   colorimetric	   assay	   was	   determined	   to	   be	   effective	   for	   determining	   the	  
concentration	  of	  both	  heparin	  and	  chitosan	  solutions	  on	  a	  wide	  range.	  It	  was	  also	  determined	  
that	   pH	   has	   a	   significant	   influence	   on	   the	   color-­‐producing	   reaction.	   This	   means	   that	   excess	  
chitosan,	  heparin,	  or	  mixtures	  of	  the	  two	  polymers	  will	  be	  indistinguishable	  in	  the	  supernatant.	  
This	   assay	   was	   performed	   using	   2-­‐20	   cP	   chitosan	   to	   enable	   homogenization	   and	   complete	  
reaction;	   higher	   viscosity	   chitosan	   prevents	   homogenization	   and	   centrifugation,	   which	   is	  
necessary	   to	   remove	   supernatant.	   Homogeneity	   of	   Hep-­‐CS	   hydrogels	   is	   an	   obstacle	   for	   any	  
light-­‐	   or	   color-­‐based	   quantification	  method;	   for	   this	   reason,	   the	   absorbance	   study	   should	   be	  
used	  more	  as	  a	  guide	  than	  an	  absolute	  measurement	  of	  degree	  of	  gelation.	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   The	  modified	  chitosan	  hydrogel	  was	  previously	  described	  and	  partially	  characterized	  in	  
research	   at	   the	   LVID.	   The	   primary	   difficulty	   with	   this	   hydrogel	   was	   the	   in	   vitro	   drug	   release	  
study.	   Initial	   protocols	   and	   previous	   studies	   utilized	   FITC-­‐BSA,	   a	   highly	   sensitive	   fluorescent	  
protein,	   as	   the	   model	   protein	   for	   release	   studies.	   Multiple	   iterations	   of	   this	   study	   were	  
inconclusive	  because	  of	  the	  sensitivity	  of	  FITC	  to	  varying	  pH.	  Sampling	  volume	  was	  an	  additional	  
factor	   that	   may	   have	   confounded	   initial	   studies.	   Initial	   sampling	   volume	   was	   10%	   of	   the	  
dialysate,	  which	  caused	  drastic	  dilution	  by	  the	  end	  of	  the	  experiment.	  Mathematically,	  dilution	  
factors	  aren’t	  confounding,	  but	  the	  highly	  varying	  concentration	  gradients	  and	  introduction	  of	  
new	  PBS	  is	  a	  variable	  that	  was	  later	  eliminated.	  	  
The	  final	  protocol	  utilized	  Alexa	  Fluor	  488	  (AF488)	  as	  the	  fluorescent	  marker	  conjugated	  
to	   IL-­‐12.	  AF488	   is	  stable	  on	  the	  range	  of	  physiological	  pH	  values	  and	  did	  not	  appear	  to	  decay	  
significantly	  over	  the	  span	  of	  one	  week.	  Furthermore,	  by	  releasing	  a	  tagged	  therapeutic	  protein	  
of	  interest,	  the	  data	  will	  more	  accurately	  represent	  the	  true	  release	  kinetics	  of	  the	  hydrogel	  and	  
modified	   chitosan	   solution	   and	   hold	   more	   value.	   While	   the	   IL-­‐12/AF488	   release	   study	   was	  
replicated	  4	  times,	  only	  one	  of	  the	  graphs	  is	  represented	  in	  this	  review.	  Unexplained	  variance	  
was	   observed	   from	   24	   to	   72	   hours	   in	   the	   other	   experiments,	   but	   final	   cumulative	   protein	  
release	  was	  consistent	  across	  trials.	   	  Variance	   in	   fluorescence-­‐based	  experiments	   inspired	  the	  
use	  of	  ELISA	  (Enzyme-­‐Linked	  Immunosorbent	  Assay)	  as	  a	  detection	  and	  quantification	  method.	  
Experimental	   setup	  was	   held	   consistent	  with	   previous	   studies,	   but	   IL-­‐12/AF488	  was	   replaced	  
with	   mouse	   IL-­‐12	   without	   AF488.	   Protein	   quantity	   in	   each	   sample	   was	   quantified	   using	   a	  
colorimetric	  ELISA	  assay.	  Data	  was	  inconclusive	  and	  is	  not	  included	  in	  this	  report.	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   In	   vivo	   IL-­‐12	   residency	   studies	   successfully	   modeled	   protein	   retention	   of	   different	  
release	  platforms.	  Results	  of	   the	  hydrogel’s	   retention,	  however,	   is	  not	   as	  expected.	   The	  mCS	  
hydrogel	  was	  hypothesized	  to	  retain	  the	  highest	  amount	  of	  protein,	  but	  the	  data	  suggests	  that	  
mCS	   solution	   retains	   a	   greater	   amount	   of	   protein	   over	   a	   longer	   period	   of	   time.	   This	  may	   be	  
attributed	   to	   the	   catalyst-­‐driven	   decomposition	   of	   the	   hydrogel;	   it	   was	   determined	   that	  
increasing	   volumes	   of	   catalyst	   increases	   the	   rate	   of	   degradation	   of	   hydrogel	   after	   initial	  
formation.	  Modified	  chitosan	  solution	  was	  compared	   to	  Protasan,	   the	  standard	   IL-­‐12	  delivery	  
solution	  used	  to	  eliminate	  tumors	  in	  mouse	  models,	  to	  evaluate	  whether	  or	  not	  results	  of	  these	  
studies	   have	   thus	   far	   improved	   protein	   retention.	   The	   modified	   chitosan	   solution	   retained	  
significantly	   more	   protein	   than	   Protasan	   over	   7	   days.	   There	   is	   discrepancy	   in	   the	   percent	  
protein	   retention	  of	  modified	   chitosan	  between	   the	   two	   individual	   studies;	   the	  mCS	   solution	  
retained	  more	  than	  twice	  the	  amount	  of	  protein	  in	  the	  hydrogel	  comparison	  study	  than	  in	  the	  
Protasan	  comparison	   study.	   For	   this	   reason,	  a	   third	   study	   is	  ongoing	   to	   re-­‐evaluate	   retention	  
capabilities	  of	  the	  mCS	  solution,	  and	  PBS,	  and	  mCS	  hydrogel	  without	  catalyst	  to	  prevent	  rapid	  
degradation.	  
	   Results	   of	   the	   investigations	   of	   both	  of	   these	   hydrogels	   provide	   a	   platform	   for	   future	  
pre-­‐clinical	  trials.	  These	  studies	  have	  been	  used	  to	  evaluate	  varying	  formulations	  of	  these	  two	  
hydrogels	  and	  mCS	  solution	  for	  intratumoral	  delivery	  of	  IL-­‐12.	  By	  understanding	  the	  properties	  
of	   these	  hydrogels	   and	   controlling	   the	   release	  of	   IL-­‐12,	  we	  may	  be	  able	   to	   increase	   localized	  
immune	   stimulation,	   enhance	   elimination	   of	   solid	   tumors,	   and	   reduce	   widespread	  
immunotoxicity.	   If	   successful,	   this	   conjugation	  could	  be	  directly	   translatable	   to	   the	  clinic	  as	  a	  
low-­‐cost	  and	  durable	  treatment	  for	  solid	  tumors.	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5.	  Appendix	  
Protocol	  1:	  Heparin-­‐Chitosan	  Hydrogel	  Preparation	  
1. Prepare	  desired	  chitosan	  solution	  	  (2X	  desired	  final	  concentration)	  
a. Dissolve	  chitosan	  (Chitoclear)	  solution	  in	  2%	  acetic	  acid	  
2. Prepare	  desired	  heparin	  solution	  (2X	  desired	  final	  concentration)	  
a. Dissolve	  heparin	  powder	  in	  PBS	  	  
3. Add	  0.5	  final	  volume	  heparin	  solution	  to	  a	  suitable	  centrifuge	  tube	  
4. Add	  0.5	   final	   volume	   chitosan	   solution	   to	   heparin	   solution,	   using	   fluidic	   forces	   to	  mix	  
solutions	  together	  
5. Allow	  solutions	  to	  react;	  reaction	  should	  occur	  in	  fewer	  than	  20	  seconds	  
	  
Protocol	  2:	  Colorimetric	  Assay	  for	  Heparin	  and	  Chitosan	  Detection	  	  
1. Gel	  preparation	  
a. Combine	   chitosan	   (Chitoclear,	   <20	   cP,	   Primex)	   and	   heparin	   solutions	   using	   a	  
pipette	  tip	  to	  stir	  
b. Homogenize	  mixture	  using	  benchtop	  vortex	  
c. Centrifuge	  gel	  (and	  counterbalance)	  at	  6000	  rpm	  for	  3	  minutes	  
d. Remove	  200	  uL	  supernatant	  and	  add	  to	  new	  microcentrifuge	  tube	  
2. Control	  preparation	  
a. Dissolve	   chitosan	   (Chitoclear,	   <20cp,	   Primex)	   at	   5mg/mL	   in	   2%	   acetic	   acid	   and	  
create	  8	  2-­‐fold	  dilutions	  
b. Adjust	  pH	  of	  CS	  solutions	  to	  5.5	  using	  10M	  NaOH	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c. Dissolve	  heparin	  at	  10mg/mL	  in	  PBS	  and	  create	  8	  2-­‐fold	  dilutions	  	  
d. adjust	  pH	  of	  heparin	  solutions	  to	  5.5	  using	  99.9%	  acetic	  acid	  
e. Add	  200	  uL	  of	  each	  solution	  to	  microcentrifuge	  tubes	  
3. Add	   100	   uL	   NaNO2	   (0.5M)	   to	   each	   microcentrifuge	   tube,	   lightly	   mixing	   solutions	   by	  
rolling	  
4. Incubate	  microcentrifuge	  tubes	  in	  80C	  water	  bath	  for	  30	  minutes	  
5. Remove	  solutions	  from	  water	  bath,	  allow	  to	  cool	  for	  2	  minutes	  
6. Add	  200	  uL	  NaOH(	  0.1M)	  and	  500	  uL	  thiobarbituric	  acid	  (0.4M),	  lightly	  mix	  by	  inversion	  
7. Incubate	  microcentrifuge	  tubes	  in	  80C	  water	  bath	  for	  10	  minutes	  
8. Remove	  microcentrifuge	  tubes	  and	  allow	  to	  cool	  for	  10	  minutes	  
9. Transfer	  80	  uL	  of	  each	  solution	  into	  a	  labeled	  96-­‐well	  plate	  and	  measure	  absorbance	  at	  
555nm	  
	  
Protocol	  3:	  Release	  Kinetics	  Determination	  Using	  Fluorescent	  Proteins	  
1. Prepare	   release	   solutions	   (in	   triplicate)	   as	   prescribed	   desired	   and	   load	   with	   desired	  
concentration	  of	  fluorescent	  protein	  
2. Load	  release	  solutions	  into	  Float-­‐A-­‐Lyzers	  (pre-­‐treated	  per	  product	  sheet	  protocol)	  
a. Float-­‐A-­‐Lyzers	  should	  be	  selected	  based	  on	  protein	  size.	  Molecular	  weight	  cutoff	  
of	   protein	   should	   be	   greater	   than	   the	   molecular	   weight	   of	   the	   protein,	   but	  
smaller	  than	  the	  molecular	  weight	  of	  the	  polymer	  or	  components	  of	  the	  release	  
solution	  
3. Add	  25	  mL	  of	  1X	  PBS	  to	  a	  50	  mL	  centrifuge	  tube	  for	  each	  Float-­‐A-­‐Lyzer	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4. Add	  Float-­‐A-­‐Lyzers	  to	  centrifuge	  tubes,	  wrap	  tubes	  and	  lids	  in	  aluminum	  foil	  to	  prevent	  
light	  exposure,	  and	  place	  in	  shaker	  at	  37C	  and	  200	  rpm	  
5. Take	  200	  uL	  samples	  of	  the	  dialysate	  (PBS)	  at	  prescribed	  time	  intervals	  and	  add	  to	  black	  
microcentrifuge	  tubes;	  keep	  samples	  at	  room	  temperature	  
6. Upon	  completion	  of	   study,	   add	  100uL	  of	  each	   sample	   to	  a	  black-­‐welled,	   clear-­‐bottom	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